Norway and its largest life sciences market, the Oslo region, are characterised by their outstanding level of biomedical research and valuable discoveries within the life sciences.
The Research Council of Norway has recently completed a mid-term evaluation of eight Centres of Excellence that were inaugurated in 2007. Oslo Cancer Cluster member, Centre for Cancer Biomedicine (CCB) was ranked with the highest obtainable score, “exceptionally good”.
A common hope in Norwegian life science circles in general and amongst Oslo Cancer Cluster’s stakeholders in particular is that success will breed success. The signs are encouraging and already a group are emerging who have unofficially been called the “New Kids on the Block” - Targovax, Ultimovacs, Nordic Nanovector and Oncoinvent.
Oslo Bio Update Survey shows confidence holding. Latest news from Neomed, Algeta, Targovax, Axis-Shield, Medistim, PCI Biotech, Affitech, and Navamedic.
Useful links arranged by subject
All items >